<DOC>
	<DOCNO>NCT00006249</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . It yet know treatment effective observation follow surgery stage III melanoma . PURPOSE : Randomized phase III trial determine effectiveness interferon alfa treat patient undergone surgery stage III melanoma .</brief_summary>
	<brief_title>Interferon Alfa Following Surgery Treating Patients With Stage III Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect adjuvant therapy pegylated interferon alfa v observation , term distant metastases-free survival , patient previously resect stage III melanoma . - Compare overall survival patient treatment pegylated interferon alfa v observation . - Determine toxicity pegylated interferon alfa patient . - Determine compliance patient treat pegylated interferon alfa . - Compare quality life patient treatment pegylated interferon alfa v observation . OUTLINE : This randomize , multicenter study . Patients stratify accord type nodal involvement ( N1 v N2 ) , number positive node ( 1 vs 2-4 v 5 v assess ) , Breslow primary ( T1-2 v T3 v T4 v unknown ) , ulceration primary tumor ( absent v present vs unknown ) , sex , center . Patients randomize one two treatment arm . - Arm I : Patients receive pegylated interferon alfa subcutaneously weekly 5 year . - Arm II : Patients undergo observation . Treatment continue absence distant metastasis unacceptable toxicity . Quality life assess baseline , month 3 , 12 , 24 , 36 , 48 , 60 . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 1,200 patient ( 600 per treatment arm ) accrue study within 1.5-2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously resect stage III primary cutaneous melanoma unknown primary regional lymph node involvement N1 disease Microscopic , nonpalpable nodal involvement Primary melanoma stage clinically inapparent N1 regional lymph node metastasis ( T14 , N1 , M0 ) detect elective lymph node dissection sentinel node biopsy N2 disease Palpable nodal involvement synchronous primary melanoma apparent nodal disease prior excision ( pT , N2 , M0 ) Regional lymph node recurrence interval surgery primary melanoma depth ( T14 , rN2 , M0 ) Complete resection primary melanoma adequate surgical margin Full lymphadenectomy must perform within 70 day study No mucous membrane melanoma ocular melanoma No evidence distant nonregional lymph node metastases transit metastasis ( even previously resect ) No incompletely resect disease due gross extracapsular extension PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : SGOT SGPT less 2 time upper limit normal No active hepatitis Renal : Creatinine le 2.0 mg/dL Cardiovascular : No severe cardiovascular disease include follow : Arrhythmias require chronic treatment Congestive heart failure ( New York Heart Association class III IV ) Symptomatic ischemic heart disease Other : No prior malignancy within past 5 year except surgically cure nonmelanomatous skin cancer carcinoma situ cervix No thyroid dysfunction unresponsive therapy No uncontrolled diabetes mellitus No active autoimmune disease No active and/or uncontrolled infection No history neuropsychiatric disorder require hospitalization No known active alcohol drug abuse HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon alfa No prior immunotherapy melanoma No concurrent immunologic biologic therapy No concurrent colony stimulate factor include epoetin alfa filgrastim ( GCSF ) Chemotherapy : No prior chemotherapy melanoma No concurrent chemotherapy Endocrine therapy : No prior hormonal therapy melanoma No concurrent hormonal therapy No concurrent chronic systemic corticosteroid therapy Radiotherapy : No prior radiotherapy melanoma No concurrent radiotherapy Surgery : See Disease Characteristics Recovered prior recent surgery Other : At least 30 day since prior experimental therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>stage III melanoma</keyword>
</DOC>